Shots:

• Ocuphire will receive $35M up front, $10M milestones upon FDA approval & is eligible to receive additional regulatory & sales milestones along with royalties. The companies collaborated for Nyxol across 3 indications in the US, EU, Japan, India, China & other markets globally
• Famy will be responsible to fund & commercialize the development of Nyxol eye drops in the US incl. clinical, manufacturing & regulatory activities required for FDA approval of all 3 Nyxol indications, incl. Nyxol+Low-Dose Pilocarpine

• The activities will be managed by Ocuphire. Famy will lead the development in non-US markets. Nyxol is currently being studied in the P-III trial for presbyopia and NVD while NDA submission for RM is expected in Q4’22

Ref: Globenewswire | Image: Ocuphire